@article{UllmannSchmidtHieberBertzetal.2016,
  author    = {Ullmann, Andrew J. and Schmidt-Hieber, Martin and Bertz, Hartmut and Heinz, Werner J. and Kiehl, Michael and Kr{\"u}ger, William and Mousset, Sabine and Neuburger, Stefan and Neumann, Silke and Penack, Olaf and Silling, Gerda and Vehreschild, J{\"o}rg Janne and Einsele, Hermann and Maschmeyer, Georg},
  title     = {Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016},
  series = {Annals of Hematology},
  volume    = {95},
  journal   = {Annals of Hematology},
  number    = {9},
  organization    = {Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation)},
  doi       = {10.1007/s00277-016-2711-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-187587},
  pages     = {1435-1455},
  year      = {2016},
  abstract  = {Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical challenge. This is a guideline provided by the AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology). A core group of experts prepared a preliminary guideline, which was discussed, reviewed, and approved by the entire working group. The guideline provides clinical recommendations for the preventive management including prophylactic treatment of viral, bacterial, parasitic, and fungal diseases. The guideline focuses on antimicrobial agents but includes recommendations on the use of vaccinations. This is the updated version of the AGHIO guideline in the field of allogeneic haematopoietic stem cell transplantation utilizing methods according to evidence-based medicine criteria.},
  language  = {en}
}
@article{HeimannPenackHeinzetal.2019,
  author    = {Heimann, Sebastian M. and Penack, Olaf and Heinz, Werner J. and Rachow, Tobias and Egerer, Gerlinde and Kessel, Johanna and Claßen, Annika Y. and Vehreschild, J{\"o}rg Janne},
  title     = {Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals},
  series = {International Journal of Infectious Diseases},
  volume    = {83},
  journal   = {International Journal of Infectious Diseases},
  doi       = {10.1016/j.ijid.2019.04.006},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-319567},
  pages     = {130-138},
  year      = {2019},
  abstract  = {Objectives Novel formulations (gastro-resistant tablet and intravenous solution) of posaconazole (POS) have been approved in prophylaxis and therapy of invasive fungal diseases (IFDs). Study aim was to analyze treatment strategies and clinical effectiveness. Methods We set up a web-based registry on www.ClinicalSurveys.net for documentation of comprehensive data of patients who received novel POS formulations. Data analysis was split into two groups of patients who received novel POS formulations for antifungal prophylaxis (posaconazole prophylaxis group) and antifungal therapy (posaconazole therapy group), respectively. Results Overall, 180 patients (151 in the posaconazole prophylaxis group and 29 in the posaconazole therapy group) from six German tertiary care centers and hospitalized between 05/2014 - 03/2016 were observed. Median age was 58 years (range: 19 - 77 years) and the most common risk factor for IFD was chemotherapy (n = 136; 76\%). In the posaconazole prophylaxis group and posaconazole therapy group, median POS serum levels at steady-state were 1,068 μg/L (IQR 573-1,498 μg/L) and 904 μg/L (IQR 728-1,550 μg/L), respectively (P = 0.776). During antifungal prophylaxis with POS, nine (6\%) probable/proven fungal breakthroughs were reported and overall survival rate of hospitalization was 86\%. The median overall duration of POS therapy was 18 days (IQR: 7 - 23 days). Fourteen patients (48\%) had progressive IFD under POS therapy, of these five patients (36\%) died related to or likely related to IFD. Conclusions Our study demonstrates clinical effectiveness of antifungal prophylaxis with novel POS formulations. In patients treated for possible/probable/proven IFD, we observed considerable mortality in patients receiving salvage treatment and with infections due to rare fungal species.},
  language  = {en}
}